Asston Pharmaceuticals Ltd
₹112.90▲ +5.37 (+4.99%)
APL·BSE·Capital Goods
Market Cap
96.10 Cr
PE Ratio
22.95
Volume
15,000
Day High - Low
112.90 - 112.90
52W High-Low
126.10 - 60.00
₹112.90▲ +5.37 (+4.99%)
Market Cap96.10 Cr
PE Ratio22.95
Volume15,000
Day High - Low112.90 - 112.90
52W High-Low126.10 - 60.00
Asston Pharmaceuticals Ltd (APL): company summary
The company's annual revenue grew 1.7% and net profit rose 0.5%, but the latest quarter saw a sharp drop in net profit, falling 75.4% year-on-year to ₹0 crore, while revenue increased 10.8% to ₹10 crore.
Asston Pharmaceuticals Ltd (APL) is a micro-cap Capital Goods company valued at ₹96 crore operating in Other Electrical Equipment on the NSE and BSE.
- Recent price move
- Asston Pharmaceuticals Ltd last traded at ₹112.9, up 4.99% on the day.
- Recent developments
- 2026-10-06: APL Apollo's Q2 volume growth rebounded, with sustained volume growth and margin protection expected to determine its future trajectory. 2026-09-07: Nuvama favours APL Apollo as pipe demand recovery nears, citing strong growth and market share gains as key factors.
- Financial performance
- The company's annual revenue grew 1.7% and net profit rose 0.5%, but the latest quarter saw a sharp drop in net profit, falling 75.4% year-on-year to ₹0 crore, while revenue increased 10.8% to ₹10 crore. The net profit margin narrowed slightly to 15.2% from 15.4% in the prior year.
- Valuation multiples
- The stock trades at 22.9 times earnings, 1.76 times book value.
- Things to watch
- The latest quarter net profit fell 75.4% to ₹0 crore, and the net profit margin narrowed by 0.2 percentage points. The stock is 14.7% below its 52-week high, and the company's latest quarter net profit is significantly lower than the same quarter a year earlier.
- Where it stands
- The company's annual revenue and net profit grew modestly, but the latest quarter saw a dramatic decline in net profit. The stock is 14.7% below its 52-week high, and the latest quarter net profit fell sharply to ₹0 crore. The net profit margin also narrowed slightly.
Summarised by DocStoX's model on 2026-10-18 from company filings, exchange data and news. This is a factual summary, not a rating or a recommendation. Informational only, not investment advice. Consult a SEBI-registered adviser before investing.
DocStoX Score
5.8/10
Fair
Fair Value
Sign in to see
ROE
9.95%
Average
P/E
22.95x
Fair
Debt / Equity
0.13
Low
Industry
Capital Goods
Other Electrical Equipment
Overall View
Fair
Price performance
52W₹60.00
₹126.10
DocStoX take
Supported by growth (8.0) and momentum (7.5), but held back by valuation (3.6).
DocStoX score
Low confidence5.8
/10
Fair
Quality
Modest
ROE 9.9%
Valuation
Rich
P/E 22.9×
Growth
Strong
Revenue +57.3% 3Y CAGR
Risk
Moderate
D/E 0.13
Momentum
Strong
80% of 52-week range
At a glance
Market Cap
₹96 Cr
52W High / Low
₹126 / ₹60
Dividend Yield
0.00%
Promoter Holding
50.66%
EPS (TTM)
₹4.92
Book Value
₹45.65
Key highlights
- Revenue compounding 57% a year
- Profit compounding 54% a year
- Low leverage — D/E 0.13
- Small ₹96 cr company — thinner liquidity
4 Positives1 Watchout
Growth
Financials
Technicals
Peers
News
Forecasts
About the company
More data
Filings, corporate actions and ownership detail — opened on demand.
More Capital Goods stocks · Other Electrical Equipment
Explore Asston Pharmaceuticals Ltd’s valuation
Free deep-dive tools · no sign-up
Fair ValueOur fair-value estimate, upside, and Bear/Base/Bull scenarios.Intrinsic ValueGraham & earnings-power intrinsic value with margin of safety.DCFDiscounted cash flow — free cash flow, growth, value per share.ValuationP/E, P/B, earnings yield and the full multiples picture.Financial RatiosProfitability, leverage and efficiency ratios at a glance.PeersHow it stacks up against its closest listed competitors.
Asston Pharmaceuticals Ltd peers in Capital Goods
Other Capital Goods stocks on the NSE & BSE. See the full Capital Goods sector list.
Related tools & concepts
Value Asston Pharmaceuticals Ltd with the ratios and calculators DocStoX uses in its analysis.
P/E RatioPrice to earningsReturn on Equity (ROE)ProfitabilityROCECapital efficiencyDebt to EquityLeverageP/B RatioPrice to bookNet Profit MarginBottom-line efficiencyDCF / Intrinsic ValueEstimate fair valueCAGR CalculatorAnnualised returnDividend YieldIncome on pricePosition SizeRisk-based sizingBrokerage CalculatorCharges on a tradeSIP CalculatorSystematic investing